Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | XDH | P47989 | 4/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HES1 | Q14469 | 2/20 | 1.00 |
| ▸ | FANCF | Q9NPI8 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rutin SCHEMBL15263233 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL13696608 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL802819 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL20576343 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL13696392 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21424757 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL23663918 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21013017 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21325433 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT | |
| Rutin SCHEMBL21699244 | 1.00 | KDM4E (1.00) | KDM4EXDHMAOAEPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463311-B1 | COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION | NATTOCAT LLC (US) | 2023-02-22 | — | — | EP | claimed |
| US-11065310-B2 | Compositions and methods for thromboembolism dissolution | Nattocat, LLC (US) | 2021-07-20 | — | — | US | claimed |
| US-20200254071-A1 | COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION | Nattocat, LLC | 2020-08-13 | — | — | US | claimed |
| EP-3463311-A1 | COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION | Nattocat, LLC (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017205790-A1 | COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION | RAISZADEH MICHELLE MONIER (US) | 2017-11-30 | — | — | WO | claimed |
| EP-4349370-A1 | TRANSCUTOL-POLYOL-ACTIVE AGENT TERNARY COMPLEX, PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING SAME, METHOD FOR OBTAINING SAME AND USE THEREOF IN DIFFERENT PATOLOGIES | Fundación Gaiker (ES) | 2024-04-10 | — | — | EP | disclosed |
| US-RE49873-E1 | APP specific bace inhibitors (ASBIs) and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3607946-B1 | APP SPECIFIC BACE INHIBITORS (ASBIS) AND USES THEREOF | BUCK INST RES AGING (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3463311-B1 | COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION | NATTOCAT LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220409535-A1 | BIOLOGICAL AGENT-EXOSOME COMPOSITIONS AND USES THEREOF | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2022-12-29 | — | — | US | disclosed |
| US-11065310-B2 | Compositions and methods for thromboembolism dissolution | Nattocat, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10835546-B2 | App specific BACE inhibitors (ASBIs) and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2020-11-17 | — | — | US | disclosed |
| EP-1251818-A1 | GALENIC FORMULATION | MERCK PATENT GmbH (DE) | 2002-10-30 | — | — | EP | disclosed |
| US-20020155163-A1 | INTEGRATED MULTI-VITAMIN AND MINERAL COMBINATION | MARIPOSA BOTANICALS, LTD. | 2002-10-24 | — | — | US | disclosed |
| CN-1363230-A | Hypoglycemic tartarian buckwheat powder and its preparing process | WANG YAN (CN) | 2002-08-14 | — | — | CN | disclosed |
| EP-1200042-A2 | EMULSIFIER-FREE FINELY DISPERSED SYSTEMS OF THE OIL-IN-WATER TYPE | Beiersdorf AG (DE) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001054653-A1 | GALENIC FORMULATION | MERCK PATENT GMBH (DE) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001005361-A2 | EMULSIFIER-FREE FINELY DISPERSED SYSTEMS OF THE OIL-IN-WATER TYPE | BEIERSDORF AG (DE) | 2001-01-25 | — | — | WO | disclosed |
| US-5472699-A | A skin protective mixture comprising an oil absorbing powder, a botanical astringent and a sebum production regulating compound; anti-oil secretion | AVON PRODUCTS, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| US-5415861-A | Skin treatment, astringents and powders | AVON PRODUCTS, INC. (US) | 1995-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835546-B2 | App specific BACE inhibitors (ASBIs) and uses thereof | APP, BACE1, GRN | KDM4E 3479/4885XDH 1344/4885MAOA 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.